1. Home
  2. BRIA vs SKYE Comparison

BRIA vs SKYE Comparison

Compare BRIA & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRIA
  • SKYE
  • Stock Information
  • Founded
  • BRIA 2011
  • SKYE 2012
  • Country
  • BRIA Singapore
  • SKYE United States
  • Employees
  • BRIA N/A
  • SKYE N/A
  • Industry
  • BRIA
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRIA
  • SKYE Health Care
  • Exchange
  • BRIA NYSE
  • SKYE Nasdaq
  • Market Cap
  • BRIA 86.3M
  • SKYE 80.7M
  • IPO Year
  • BRIA 2024
  • SKYE N/A
  • Fundamental
  • Price
  • BRIA $3.10
  • SKYE $3.41
  • Analyst Decision
  • BRIA
  • SKYE Buy
  • Analyst Count
  • BRIA 0
  • SKYE 6
  • Target Price
  • BRIA N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • BRIA 30.7K
  • SKYE 178.5K
  • Earning Date
  • BRIA 02-19-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • BRIA N/A
  • SKYE N/A
  • EPS Growth
  • BRIA N/A
  • SKYE N/A
  • EPS
  • BRIA 92.24
  • SKYE N/A
  • Revenue
  • BRIA $55,755,669.00
  • SKYE N/A
  • Revenue This Year
  • BRIA N/A
  • SKYE N/A
  • Revenue Next Year
  • BRIA N/A
  • SKYE N/A
  • P/E Ratio
  • BRIA $0.03
  • SKYE N/A
  • Revenue Growth
  • BRIA 8.03
  • SKYE N/A
  • 52 Week Low
  • BRIA $2.90
  • SKYE $2.31
  • 52 Week High
  • BRIA $4.38
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • BRIA N/A
  • SKYE 52.82
  • Support Level
  • BRIA N/A
  • SKYE $2.70
  • Resistance Level
  • BRIA N/A
  • SKYE $3.29
  • Average True Range (ATR)
  • BRIA 0.00
  • SKYE 0.45
  • MACD
  • BRIA 0.00
  • SKYE 0.05
  • Stochastic Oscillator
  • BRIA 0.00
  • SKYE 41.27

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: